Ambien CR Generics Need Extra Bioequivalence Tests, Sanofi Argues To FDA
Executive Summary
Sanofi-Aventis is requesting that FDA require additional bioequivalence tests for generic versions of its insomnia product Ambien CR (zolpidem extended-release)
You may also be interested in...
Sleep Agents Update Warnings As FDA Seeks Further Study Of “Complex” AEs
Questions about the safety of drugs in the sedative-hypnotic class could warrant additional clinical trials to further evaluate the complex sleep-related behaviors associated with the drugs, FDA said in announcing stronger warnings for the class March 14
Ambien CR Approval Includes Sleep Maintenance, Long-Term Use
The approval of Sanofi-Aventis' Ambien CR (zolpidem extended-release) includes claims for sleep maintenance and long-term use that will allow the insomnia medication to compete against newer agents
Big Pharma Still Hopeful For Next Mega Drugs To Supplement Sales
Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.